Publication & Citation Trends
Most Cited Works
Publications
23 total
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i> PDF
Cited by 335
OpenAlex
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia PDF
Cited by 234
OpenAlex
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
Cited by 118
OpenAlex
Discovery of <i>N</i>-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor PDF
Cited by 108
OpenAlex
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay PDF
Cited by 100
OpenAlex
SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103) PDF
Cited by 7
OpenAlex
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
Cited by 105
Semantic Scholar
Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC
Cited by 0
Semantic Scholar
Research Topics
Histone Deacetylase Inhibitors Research
(19)
Protein Degradation and Inhibitors
(17)
Epigenetics and DNA Methylation
(6)
Peptidase Inhibition and Analysis
(4)
Cancer-related Molecular Pathways
(3)
Frequent Co-Authors
Affiliations
Duke University
Princess Margaret Cancer Centre
Gabrail Cancer Center
Sidney Kimmel Cancer Center
Pyrogenesis (Canada)